← FDA DRUG APPROVALS

FDA NDA · NDA021131

ZYVOX

linezolid

Sponsor: PFIZER

APPLICATION
NDA021131
TYPE
NDA
ORIGINAL APPROVAL
2000-04-18
LATEST ACTION
2026-06-09
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription, Discontinued

Products

ZYVOX · ReferencePrescription
LINEZOLID 600MG/300ML (2MG/ML) · SOLUTION · INTRAVENOUS
ZYVOX · ReferencePrescription
LINEZOLID 200MG/100ML (2MG/ML) · SOLUTION · INTRAVENOUS
ZYVOX · ReferenceDiscontinued
LINEZOLID 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION · INTRAVENOUS

Approval history

2026-06-09Labeling · Supplement 48 · standardLetterAP
2024-06-27Labeling · Supplement 44 · standardLabelAP
2023-07-18Labeling · Supplement 41 · standardLetterAP
2021-11-10Labeling · Supplement 40 · standardLabelAP
2021-10-26Labeling · Supplement 39 · standardLetterAP
2021-09-01Labeling · Supplement 38 · standardLetterAP
2021-07-16Labeling · Supplement 37 · standardLetterAP
2020-08-05Labeling · Supplement 34 · standardLabelAP
2020-08-05Labeling · Supplement 35 · standardLabelAP
2018-02-01Labeling · Supplement 30 · standardLabelAP
2017-07-13Labeling · Supplement 28 · standardLetterAP
2015-06-05Labeling · Supplement 29 · standardLetterAP
2014-07-28Manufacturing (CMC) · Supplement 27 · priorityAP
2014-01-24Labeling · Supplement 26 · standardLetterAP
2013-05-03Labeling · Supplement 21 · standardLabelAP
2013-05-03Labeling · Supplement 22 · standardLabelAP
2012-02-13Labeling · Supplement 24 · standardLetterAP
2010-07-16Labeling · Supplement 20 · unknownLabelAP
2009-12-08Labeling · Supplement 17 · standardLabelAP
2008-06-20Labeling · Supplement 13 · standardLetterAP
2008-06-20Labeling · Supplement 14 · standardLetterAP
2007-09-18Manufacturing (CMC) · Supplement 16 · priorityAP
2007-08-02Manufacturing (CMC) · Supplement 15 · priorityAP
2007-04-26Labeling · Supplement 12 · standardLetterAP
2005-11-02Labeling · Supplement 11 · standardLetterAP
2005-05-12Labeling · Supplement 9 · standardLabelAP
2005-05-12Efficacy · Supplement 10 · priorityLetterAP
2005-02-10Labeling · Supplement 8 · standardLetterAP
2004-06-23Efficacy · Supplement 7 · priorityLetterAP
2004-01-05Labeling · Supplement 6 · standardLetterAP
2003-07-22Efficacy · Supplement 4 · standardLetterAP
2002-12-19Labeling · Supplement 2 · standardLetterAP
2002-12-19Efficacy · Supplement 3 · priorityReviewAP
2001-02-06Labeling · Supplement 1 · standardAP
2000-04-18Type 3 - New Dosage Form · Original · priorityLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →